Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients

• Príomhchruthaitheoirí: Hassan Abolghasemi, MD (Údar), Yunes Panahi, PhD (Údar), Minoo. Ahmadinejad, MD (Údar), Gholamreza Toogeh, MD (Údar), Mehran Karimi, MD (Údar), Aziz Eghbali, MD (Údar), Nargess Bigom Mirbehbahani, MD (Údar), Bighan Keikhaei Dehdezi, MD (Údar), Zahra Badiee, MD (Údar), Hamid Hoorfar, MD (Údar), Peyman Eshghi, MD (Údar), Nader Maghsoudi, PhD (Údar), Amirhossein Sahebkar, PhD (Údar), Mohammad Gholami- Fesharaki, PhD (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Korean Pharmacopuncture Institute, 2018-06-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Objective: This study compared the safety and efficacy of Safacto® versus xyntha® in patients with severe hemophilia A. Methods: Thirty-three male patients with severe hemophilia A were randomly divided into two groups. Seventeen patients received Safacto® and 16 patients...